Propionic Acid

Propionic Acid

SCHEMBL1100328

CCC(=O)O.FC(F)(F)c1cnc2c(ccn2Cc2ccncc2)c1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
KCNQ3 O43525 2/20 0.39
KCNQ2 O43526 2/20 0.39
KCNQ4 P56696 2/20 0.39
KCNQ5 Q9NR82 2/20 0.39
AGBL2 Q5U5Z8 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
NR3C1 P04150 2/20 0.37
FGFR1 P11362 1/20 0.37
FGFR4 P22455 1/20 0.37
FLT1 P17948 1/20 0.36
KDR P35968 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HIF1A Q16665 1/20 0.36
EPAS1 Q99814 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL1099553 0.84 MAPK14 (0.43) GRIN1GRIN2BPPARDPPARAFGFR1
Ethoxycarbonyl Group SCHEMBL27728918 0.77 MEN1 (0.38) NR3C1FGFR1KDRSMN1; SMN2ALDH1A1
SCHEMBL298863 0.74 CCR9 (0.51) GRIN1GRIN2BPTGDR2
SCHEMBL1100326 0.73 FFAR1 (0.41) GRIN1GRIN2BPTGDR2SMN1; SMN2HIF1A
SCHEMBL27790858 0.72 MAPK14 (0.45) GRIN1GRIN2BCYP3A4
SCHEMBL2545450 0.72 NOD2 (0.44) GRIN1GRIN2BPTGDR2SMN1; SMN2ALDH1A1
Propionic Acid SCHEMBL1099676 0.71 GLO1 (0.45) FGFR1FGFR4ALDH1A1CYP3A4
Ethoxycarbonyl Group SCHEMBL27868528 0.70 METAP2 (0.37) GRIN1GRIN2BFGFR1FGFR4USP2
SCHEMBL31336552 0.69 FGFR1 (0.56) KCNQ3KCNQ2KCNQ4KCNQ5NR3C1
SCHEMBL26220303 0.69 FGFR1 (0.56) KCNQ3KCNQ2KCNQ4KCNQ5NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716273-B2 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI (FR) 2014-05-06 US disclosed
US-8716272-B2 N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI (FR) 2014-05-06 US disclosed
US-20120142669-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI-AVENTIS (FR) 2012-06-07 US disclosed
US-20120142670-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI-AVENTIS (FR) 2012-06-07 US disclosed
US-8153650-B2 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI-AVENTIS (FR) 2012-04-10 US disclosed
US-20100041634-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy SANOFI-AVENTIS (FR) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142670-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy ZYX, NQO2, PYCR1 GRIN1 875/4885GRIN2B 536/4885KCNQ3 929/4885
US-20120142669-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy ZYX, NQO2, PYCR1 GRIN1 875/4885GRIN2B 536/4885KCNQ3 929/4885
US-20100041634-A1 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy ZYX, NQO2, PYCR1 GRIN1 875/4885GRIN2B 536/4885KCNQ3 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.